{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:24:45Z","timestamp":1782923085530,"version":"3.54.5"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Our aim was to describe a monocentric cohort of young adult patients with juvenile idiopathic arthritis (JIA), assessing the risk of relapse after transition to adult care.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a retrospective study and collected clinical, serological, and demographic data of young adult patients (18\u201330 years old) referred to the Transition Clinic of a single Italian centre between January 2020 and March 2023. Patients with systemic-onset JIA were excluded. Primary outcome was disease relapse, defined by Wallace criteria. Risk factors were analysed by Cox proportional hazards regression.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Fifty patients with age 18\u201330 years old were enrolled in the study and followed for a median 30 months. The median disease duration at transition was 15 years. Twenty (40%) patients were on conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and 38 (76%) were on biological DMARDs through adulthood. Twenty-three patients relapsed after transitioning to adult care for a median 9-month follow-up (IQR 0\u201346.5). Most relapses involved the knees (69.6%). The univariate analysis identified monoarthritis (HR 4.67, CI 1.069\u201320.41, p value = 0.041) as the main risk factor for relapse within the first 36 months of follow-up. Early onset, ANA positivity, past and ongoing treatment with csDMARDs or bDMARDs, therapeutic withdrawal, and disease activity within 12 months before transition did not significantly influence the risk of relapse.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>In JIA patients, the risk of relapse after transitioning to adult care remains high, irrespective of disease subtype and treatment. The main risk factor for the early occurrence of articular activity is monoarticular involvement.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0298679","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T17:39:07Z","timestamp":1714671547000},"page":"e0298679","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Relapses of juvenile idiopathic arthritis in adulthood: A monocentric experience"],"prefix":"10.1371","volume":"19","author":[{"given":"Laura","family":"Scagnellato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Prosepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Lorenzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-3485","authenticated-orcid":true,"given":"Francesco","family":"Zulian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-8873","authenticated-orcid":true,"given":"Roberta","family":"Ramonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"pone.0298679.ref001","first-page":"1991","article-title":"Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997","volume":"25","author":"RE Petty","year":"1998","journal-title":"J Rheumatol"},{"key":"pone.0298679.ref002","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"RE Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"pone.0298679.ref003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-021-00332-8","article-title":"Juvenile idiopathic arthritis","volume":"8","author":"A Martini","year":"2022","journal-title":"Nat Rev Dis Primer"},{"key":"pone.0298679.ref004","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.40885","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis\u2013Associated Uveitis","volume":"71","author":"ST Angeles\u2010Han","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"pone.0298679.ref005","first-page":"449","article-title":"Towards molecular-pathology informed clinical trials in childhood arthritis to achieve precision medicine in juvenile idiopathic arthritis","volume":"82","author":"CLUSTER Consortium","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"pone.0298679.ref006","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus","volume":"46","author":"A Martini","year":"2019","journal-title":"J Rheumatol"},{"key":"pone.0298679.ref007","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/rheumatology\/keu257","article-title":"What does an adult rheumatologist need to know about juvenile idiopathic arthritis?","volume":"53","author":"EJ Coulson","year":"2014","journal-title":"Rheumatol Oxf Engl"},{"key":"pone.0298679.ref008","first-page":"1086","article-title":"Patients with juvenile idiopathic arthritis become adults: the role of transitional care","volume":"36","author":"F Conti","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"pone.0298679.ref009","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12969-022-00742-2","article-title":"Transitioning patients with juvenile idiopathic arthritis to adult care: the Nordic experience","volume":"20","author":"K Mikola","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"key":"pone.0298679.ref010","article-title":"Pediatric to Adult Transition Literature: Scoping Review and Rheumatology Research Prioritization Survey Results","author":"N Bitencourt","year":"2022","journal-title":"J Rheumatol"},{"key":"pone.0298679.ref011","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1080\/14397595.2017.1416890","article-title":"Outcome of transition phase patients with juvenile idiopathic arthritis","volume":"28","author":"H Relas","year":"2018","journal-title":"Mod Rheumatol"},{"key":"pone.0298679.ref012","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.42037","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis","volume":"74","author":"KB Onel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"pone.0298679.ref013","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis","volume":"63","author":"Childhood Arthritis Rheumatology Research Alliance (CARRA)","year":"2011","journal-title":"Arthritis Care Res"},{"key":"pone.0298679.ref014","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/sim.7992","article-title":"Minimum sample size for developing a multivariable prediction model: PART II \u2010 binary and time\u2010to\u2010event outcomes","volume":"38","author":"RD Riley","year":"2019","journal-title":"Stat Med"},{"key":"pone.0298679.ref015","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling survival data: extending the Cox model","author":"TM Therneau","year":"2000"},{"key":"pone.0298679.ref016","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/jpc.13450","article-title":"Joint hypermobility and oligoarticular juvenile idiopathic arthritis: What relationship?: Joint hypermobility in juvenile arthritis","volume":"53","author":"V Cecchin","year":"2017","journal-title":"J Paediatr Child Health"},{"key":"pone.0298679.ref017","doi-asserted-by":"crossref","first-page":"e001766","DOI":"10.1136\/rmdopen-2021-001766","article-title":"Health-related quality of life and disability in adults with juvenile idiopathic arthritis: comparison with adult-onset rheumatic diseases","volume":"7","author":"F Oliveira Ramos","year":"2021","journal-title":"RMD Open"},{"key":"pone.0298679.ref018","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12969-021-00607-0","article-title":"Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach","volume":"19","author":"M Castillo-Vilella","year":"2021","journal-title":"Pediatr Rheumatol"},{"key":"pone.0298679.ref019","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/rheumatology\/kex265","article-title":"Predictors and long-term outcome in Greek adults with juvenile idiopathic arthritis: a 17-year continuous follow-up study","volume":"56","author":"D Dimopoulou","year":"2017","journal-title":"Rheumatology"},{"key":"pone.0298679.ref020","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3899\/jrheum.121257","article-title":"HLA-B27 Predicts a More Chronic Disease Course in an 8-year Followup Cohort of Patients with Juvenile Idiopathic Arthritis","volume":"40","author":"L Berntson","year":"2013","journal-title":"J Rheumatol"},{"key":"pone.0298679.ref021","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12969-017-0151-7","article-title":"Radiographic damage in hands and wrists of patients with juvenile idiopathic arthritis after 29 years of disease duration","volume":"15","author":"AM Selvaag","year":"2017","journal-title":"Pediatr Rheumatol"},{"key":"pone.0298679.ref022","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12969-022-00769-5","article-title":"Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors","volume":"20","author":"J Gieling","year":"2022","journal-title":"Pediatr Rheumatol"},{"key":"pone.0298679.ref023","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.51.4.522","article-title":"Predictive value of synovial fluid analysis in juvenile chronic arthritis","volume":"51","author":"L Punzi","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"pone.0298679.ref024","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3899\/jrheum.170794","article-title":"Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factor\u2013negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication","volume":"45","author":"A Aquilani","year":"2018","journal-title":"J Rheumatol"},{"key":"pone.0298679.ref025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/1744666X.2020.1865157","article-title":"The importance of transition from pediatric to adult rheumatology care in juvenile idiopathic arthritis","volume":"17","author":"RJ de Oliveira","year":"2021","journal-title":"Expert Rev Clin Immunol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0298679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T17:39:22Z","timestamp":1714671562000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0298679"}},"subtitle":[],"editor":[{"given":"Vineet Kumar","family":"Rai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0298679","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]}}}